Sign in

Private company

BIODELIVERY SCIENCES INTERNATIONAL INC

American pharmaceutical preparations company based in Raleigh2

In its 2022 annual report the company says: “We own various trademark registrations and applications, and unregistered trademarks, including BioDelivery Sciences International, Inc., BEMA, BELBUCA, ELYXYB, BUNAVAIL, ONSOLIS and our corporate logo. We have an exclusive license to use and display the Symproic registered trademark in order to commercialize Symproic in the United States.”53

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersRaleigh, United States2
  • Incorporated inDE3
  • Business address4131 Parklake Avenue, Suite 225, Raleigh, Nc 276123
  • Filer categoryAccelerated filer3
  • Legal formCorporation2
  • LEI529900YQ5QSV2ZNM2W452
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o NATIONAL REGISTERED AGENTS, INC., 160 GREENTREE DR STE 101, 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 35156992

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

22.3%Operating margin4
50.9%Net margin4
6.5%Revenue growth, 20214
45.2%Return on equity4
$40.6MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue14¢$23.4M
  • Other costs2¢$3.2M
  • Income tax33¢$55.2M
  • Profit51¢$84.9M

Out of $166.7M in revenue.4

Where each dollar of operating cash went, fiscal 2021

  • Capital spending1¢$415.0K
  • Share buybacks29¢$11.9M
  • Kept or used elsewhere70¢$28.7M

Out of $41.0M of cash from operations.4

Financial statements

Revenue56784$166.7M in 2021+246% since 2015
0$50.0M$100.0M$150.0M$200.0M2015: $48.2M$48.2M20152016: $15.5M$15.5M2016−68%2017: $62.0M$62.0M2017+299%2018: $55.6M$55.6M2018−10%2019: $111.4M$111.4M2019+100%2020: $156.5M$156.5M2020+40%2021: $166.7M$166.7M2021+7%
Operating income56784$37.1M in 2021
-$100.0M-$50.0M0$50.0M2015: -$35.2M-$35.2M20152016: -$63.9M-$63.9M2016+82%2017: -$29.4M-$29.4M2017−54%2018: -$23.6M-$23.6M2018−20%2019: $3.7M$3.7M20192020: $33.0M$33.0M2020+783%2021: $37.1M$37.1M2021+13%
Net income56784$84.9M in 2021
-$100.0M-$50.0M0$50.0M$100.0M2015: -$37.7M-$37.7M20152016: -$67.1M-$67.1M2016+78%2017: $5.3M$5.3M20172018: -$33.9M-$33.9M20182019: -$15.3M-$15.3M2019−55%2020: $25.7M$25.7M20202021: $84.9M$84.9M2021+230%
Fiscal year2015201620172018201920202021
Revenue$48.2M5$15.5M6$62.0M7$55.6M8$111.4M4$156.5M4$166.7M4
Cost of revenue$8.1M5$11.3M5$19.5M5$15.8M8$21.6M4$24.7M4$23.4M4
Research and development$20.6M5$18.9M6$13.0M7$4.9M8$08$08
Selling, general and admin
Operating expenses$106.2M4
Operating income-$35.2M5-$63.9M6-$29.4M7-$23.6M8$3.7M4$33.0M4$37.1M4
Interest$2.5M5$3.3M6$8.6M7$10.2M7$19.0M7
Income before tax$29.6M4
Income tax$05$05-$16.0M7$13.0K8$5.0K4$252.0K4-$55.2M4
Net income-$37.7M5-$67.1M6$5.3M7-$33.9M8-$15.3M4$25.7M4$84.9M4
Earnings per share-$0.725-$1.256$0.107-$0.738-$0.184$0.264$0.854
Earnings per share (diluted)-$0.725-$1.256$0.097-$0.738-$0.184$0.244$0.824
Shares (weighted, basic)99.3M shares4
Shares (weighted, diluted)103.3M shares4

Compare BIODELIVERY SCIENCES INTERNATIONAL INC with another company

Corporate structure

BIODELIVERY SCIENCES INTERNATIONAL INC is part of a group headed by COLLEGIUM PHARMACEUTICAL, INC. 9 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BIODELIVERY SCIENCES INTERNATIONAL INC

  • Versor Investments LP Filed SC 13G/A on BIODELIVERY SCIENCES INTERNATIONAL INC, latest Feb 10, 2023 (2 filings since Feb 24, 2022)
  • Magnetar Financial LLC Filed SC 13D on BIODELIVERY SCIENCES INTERNATIONAL INC, latest Feb 24, 2022
  • Nantahala Capital Management, LLC Filed SC 13G/A on BIODELIVERY SCIENCES INTERNATIONAL INC, latest Feb 14, 2022
  • James E. Flynn Filed SC 13G/A on BIODELIVERY SCIENCES INTERNATIONAL INC, latest Feb 11, 2022
  • BlackRock Filed SC 13G/A on BIODELIVERY SCIENCES INTERNATIONAL INC, latest Feb 3, 2022
  • COLLEGIUM PHARMACEUTICAL, INC Stoughton, Massachusetts, United States
    • BIODELIVERY SCIENCES INTERNATIONAL INC Raleigh, North Carolina, United States
    • Arius Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Arius Two, Inc. Subsidiary · Delaware, United States
    • Collegium Securities Corporation Subsidiary · Massachusetts, United States
    • Ironshore Pharmaceuticals & Development, Inc. Subsidiary · Cayman Islands
    • Ironshore Pharmaceuticals Canada Inc. Subsidiary · Canada
    • Ironshore Pharmaceuticals Inc. Subsidiary · Delaware, United States
    • Ironshore Therapeutics, Inc. Subsidiary · Cayman Islands

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIODELIVERY SCIENCES INTERNATIONAL INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$520.0K4 Dec 31, 2021$471.0K8 Dec 31, 2020+10.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$114.3M4 Dec 31, 2021$111.6M4 Dec 31, 2020+2.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.7M4 Dec 31, 2021$2.7M4 Dec 31, 20200%
Intangible assets, net (excluding goodwill)$08 Dec 31, 2020$47.0K8 Dec 31, 2019−100.0%
Finite-lived intangibles, gross$91.1M4 Dec 31, 2021$81.7M4 Dec 31, 2020+11.5%
Accumulated amortization$29.5M4 Dec 31, 2021$28.3M4 Dec 31, 2020+4.4%
Finite-lived intangibles, net$61.5M4 Dec 31, 2021$53.4M4 Dec 31, 2020+15.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$23.7M4 Dec 31, 2021$17.4M4 Dec 31, 2020+35.9%
Work in process$9.9M4 Dec 31, 2021$9.9M4 Dec 31, 2020−0.2%
Finished goods$14.3M4 Dec 31, 2021$6.4M4 Dec 31, 2020+124.7%

Leadership

Who has led BIODELIVERY SCIENCES INTERNATIONAL INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mark A. Sirgo2007–2017
  2. Herm Cukier2018–2020
  3. Jeffrey Allen Bailey2020–2022

Chair

  1. Francis E. Odonnell Jr.2015

President

  1. Mark A. Sirgo2007–2017
  2. Scott M. Plesha2018

Chief financial officer

  1. James A. McNulty2006–2013
  2. Mark A. Sirgo2006
  3. Paolantonio Ernest Robert De2013–2018
2010201520202025
Board members and other officers (26)

Former names

  • MAS ACQUISITION XXIII CORPApr 13, 2000 to Apr 18, 20003

Timeline

  1. Mar 22, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer41
  2. Feb 15, 20228-K Entered a material agreement; Bylaws or fiscal year changed; Regulation FD disclosure42
  3. Feb 14, 20228-K Entered a material agreement; Bylaws or fiscal year changed; Regulation FD disclosure43
  4. Jan 20, 20228-K Results of operations44
  5. Dec 21, 20218-K Regulation FD disclosure; Other events45
  6. Nov 3, 20218-K Results of operations46
  7. Oct 21, 20218-K Executive or director change; Other events47
  8. May 12, 2020New chief executive Jeffrey Allen Bailey becomes CEO10
  9. May 8, 2018New chief executive Herm Cukier becomes CEO11
  10. Feb 14, 2007New chief executive Mark A. Sirgo becomes CEO12

Calendar

When it reported results

  1. Jan 20, 2022Reported quarterly or annual results44
  2. Nov 3, 2021Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

69 filings to the SEC since October 2021: 1 annual reports, 1 quarterly reports, 7 major events, 36 insider forms, 6 large holders, 18 other. The latest 20:

  1. Feb 10, 2023SC 13G/A EDGAR
  2. Apr 1, 202215-12B EDGAR
  3. Mar 25, 2022EFFECT EDGAR
  4. Mar 24, 2022S-8 POS EDGAR
  5. Mar 24, 2022S-8 POS EDGAR
  6. Mar 24, 2022S-8 POS EDGAR
  7. Mar 24, 2022S-8 POS EDGAR
  8. Mar 24, 2022S-8 POS EDGAR
  9. Mar 23, 2022S-8 POS EDGAR
  10. Mar 23, 2022POS AM EDGAR
  11. Mar 22, 202225-NSE EDGAR
  12. Mar 22, 20228-K EDGAR
  13. Mar 22, 20224 EDGAR
  14. Mar 22, 20224 EDGAR
  15. Mar 22, 20224 EDGAR
  16. Mar 22, 20224 EDGAR
  17. Mar 22, 20224 EDGAR
  18. Mar 22, 20224 EDGAR
  19. Mar 22, 20224 EDGAR
  20. Mar 22, 20224 EDGAR

The 69 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 6 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 4, 2022Vollins JamesSee RemarksSale18,541$3.60$66.7KForm 4
Dec 2, 2021Sirgo Mark ADirectorBuy18,587$2.69$50.0KForm 4
Nov 19, 2021KOTLER KEVINDirectorBuy100,000$3.06$306.0KForm 4
Nov 18, 2021Sirgo Mark ADirectorBuy10,000$3.04$30.4KForm 4
Nov 18, 2021Sirgo Mark ADirectorSale10,000$3.04$30.4KForm 4
Nov 12, 2021Broadfin Capital, LLCDirectorBuy100,000$3.20$320.0KForm 4
Nov 11, 2021Sirgo Mark ADirectorBuy16,000$3.20$51.2KForm 4
Nov 5, 2021KOTLER KEVINDirectorBuy257,800$3.47$894.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How BIODELIVERY SCIENCES INTERNATIONAL INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIODELIVERY SCIENCES INTERNATIONAL INC1
  • CIK0001103021
  • Employer ID (EIN)35-20898581
  • Filer statusAccelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address4131 Parklake Avenue, Suite 225, Raleigh, NC 276121
  • Phone919 582 90501
  • Shares outstanding103,228,796 as of Mar 7, 20224
  • Public float$329.5M as of Jun 30, 20214
  • On EDGAR sinceJan 18, 20001
  • Filings1,391 in all: 4 (542), 8-K (296), SC 13G/A (63), 10-Q (42), 5 (35), SC 13G (34), 3 (33), CORRESP (26)1
    All 60 form types

    10QSB (24), SC 13D/A (23), CT ORDER (22), DEF 14A (20), UPLOAD (19), 10-K (15), S-3 (14), 424B3 (13), EFFECT (13), PRE 14A (12), 8-K/A (11), SB-2/A (11), S-8 POS (10), 4/A (8), 424B1 (8), NT 10-Q (7), 10KSB (6), S-8 (6), 10QSB/A (5), DEFA14A (5), SB-2 (5), SC 13D (5), 10-Q/A (4), 10KSB/A (4), 424B5 (4), S-3/A (4), SC TO-T/A (4), 10-K/A (3), 25-NSE (3), NT 10-K (3), SC 14D9/A (3), SC14D9C (3), 25 (2), POS AM (2), SC 14D9 (2), 10KSB40 (1), 10SB12G (1), 10SB12G/A (1), 144 (1), 15-12B (1), 3/A (1), 424B4 (1), 5/A (1), 8-A12B (1), 8-A12B/A (1), CERTBSE (1), FWP (1), RW (1), SC 14F1 (1), SC 14F1/A (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 9, 2022
    Quarterly report (10-Q) Nov 3, 2021
    Proxy statement (DEF 14A) Jun 22, 2021
    Latest 8-K (8-K) Mar 22, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53